Search results
NovaGo develops a human antibody to stimulate nerve repair after spinal cord injury by blocking Nogo-A receptor. Learn more about the company, the disease and the therapy.
The Northern Virginia Geocaching Organization (NoVAGO) was established to encourage and promote good geocaching practices and create a community of geocachers through our events and activities. We are committed to safe, responsible, and environmentally friendly geocaching.
Novago Coopérative est une coopérative agricole qui offre des services et des produits dans plusieurs secteurs d’activité, tels que les productions végétales, laitière, bovine, porcine, équine, avicole, etc. Découvrez comment devenir membre, trouver un expert, consulter les opportunités d’emploi et les événements de la coopérative.
Novago is a billing software solution that provides seamless digital billing experience and provides data analytics features. Users can scan QR codes to get digital receipts, track expenses, and enjoy personalized discounts at participating stores.
- Overview
- Clinical studies partners
- GeneratedCaptionsTabForHeroSec
Produced by
Download PDF
Stroke is the leading cause of adult disability in the developed world, affecting approximately 33 million patients worldwide and costing more than €40 billion per year in direct and indirect costs in the EU alone. Following a stroke, rapid re-establishment of blood flow can reduce tissue and neuron injury, but there is no pharmacotherapy available that can regenerate damaged regions of the brain; the mainstay of stroke treatment is rehabilitation therapy, which typically results in only modest improvements or recovery of function, leaving more than half of stroke patients severely and permanently disabled. As the global incidence of stroke is increasing at the same time as death from stroke is declining, stroke is now a disease of chronically disabled survivors, many of whom lose their independence and are forced to live in nursing homes.
NovaGo Therapeutics, a biotech start-up company that develops human antibodies that stimulate nerve repair and regeneration, is set to address this large unmet medical need. The company’s co-founder and president, Martin E. Schwab, previously discovered that neurite growth inhibitors prevent repair and regeneration in the central nervous system (CNS). Although needed for proper CNS development and maintenance, they obstruct the regenerative process following stroke or injury, limiting recovery of function. Schwab identified Nogo-A as a key inhibitor of axonal growth. Since then he has founded NovaGo Therapeutics to pursue the development of regenerative therapies for CNS disorders. A strategic partnership with biopharmaceutical company Neurimmune enabled the discovery of specifically targeted human-derived antibodies that block Nogo-A.
By inhibiting Nogo-A, NovaGo’s lead anti-Nogo-A antibody (NG004) induces neurite outgrowth—not only near the injured site but also in contralateral or other areas of the brain. The neuronal sprouting, together with rehabilitation exercise, enables significantly more recovery of function than rehab alone (Fig. 1). “Unlike a neuroprotectant, our recombinant human monoclonal antibody allows neurons to make new connections,” explained Eduardo Vianna, CEO. “This promotes the central nervous system’s regenerative healing process and neurological recovery and should allow stroke patients to recover much more function.”
Preclinical studies in rodent and non-human primate models demonstrate that anti-Nogo-A therapy is highly effective in enhancing nerve fiber repair and the formation of new fiber connections. After a cerebral stroke, animals given the antibody for 2 weeks followed by 4 weeks of rehabilitation exercises recover 70–85% of function compared with only 40% for control animals receiving rehab alone. “Our anti-Nogo-A therapy boosts the sprouting of new nerve fibers, and the newly formed circuits are stabilized by intensive training,” said Vianna. “Our results have overthrown the dogma in medicine that injuries of the brain and spinal cord will not heal and cannot be repaired.”
NovaGo’s founding and management team has a proven track record in research and drug development, and maintains international networks across academia and industry, including close collaborations with the University of Zurich and the University Hospital in Zurich, Switzerland, where the company has its headquarters. NovaGo has started a series B in...
NovaGo is a biotech start-up that develops human antibodies that block Nogo-A, a neurite growth inhibitor, to promote nerve repair and regeneration after stroke. The company’s lead candidate, NG004, is ready for phase 1 trials and has shown promising results in preclinical studies.
NovaGo is a biotech company developing human antibody therapeutics to enhance nerve repair and functional recovery after spinal cord injury. It collaborates with Neurimmune and plans to start phase 1 trials in 2024.
People also ask
Who is novago Therapeutics?
What does novago do?
How to use novago?
What is novago billing software?
NovaGo Therapeutics is a development stage biotech company focused on human antibody therapeutics for spinal cord injury | NovaGo’s fully human monoclonal antibodies have the potential to...
